Barclays Upgrades Quest Diagnostics to Overweight, Raises Price Target to $210
- Barclays upgraded Quest Diagnostics to "Overweight" and raised its price target to $210.
- Quest's large national lab network supports consolidation, faster turnaround, and negotiating power with payers.
- The upgrade signals confidence in Quest's ability to sustain volumes, reduce fixed costs, and boost margins via automation.
Barclays signals renewed faith in Quest Diagnostics' testing business
NEW YORK — Barclays upgrades Quest Diagnostics to "Overweight," raising its price target to $210, a move that reflects growing analyst confidence in the company’s position in clinical laboratory testing. The upgrade arrives as payers and providers increasingly rely on large national laboratories to deliver routine and specialty testing with scale efficiencies. Barclays’ action is read by market watchers as an endorsement of Quest’s ability to sustain volumes and leverage fixed-cost advantages across its national network.
Analysts say the upgrade underscores structural strengths in Quest’s core diagnostics franchise rather than short-term market swings. Quest operates one of the largest networks of reference labs in the U.S., which supports customer consolidation from hospitals, physicians and outpatient centers seeking standardized testing and faster turnaround. The firm’s scale also positions it to negotiate with payers and to invest in automation and data services that can drive margin improvement as testing demand stabilizes post-pandemic.
The move also highlights industry dynamics around consolidation, pricing pressure and innovation in diagnostics services. Quest faces direct competition from other national labs and emerging diagnostics firms, but an upgrade by a major bank suggests expectations that Quest’s strategic initiatives — such as partnerships, digital ordering and lab automation — can translate into steadier revenue and improved profitability. Investors and clients alike watch how Quest balances near-term reimbursement pressure with long-term opportunities in personalized medicine and diagnostic data analytics.
Analyst calls across sectors bring a varied outlook
Other broker activity this week reflects a wide-ranging market reassessment. Goldman Sachs upgrades Futu Holdings to "Buy" from "Neutral," assigning a 12-month price target of $213.39 and citing favorable capital markets conditions and client growth; Bank of America reiterates a "Buy" on Nvidia, citing its role in AI computing and networking.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

